Navigation Links
DNA Sequencing: Technologies, Markets and Companies - 2013 Report
Date:6/18/2013

DUBLIN, June 18, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing) has announced the addition of the report "DNA Sequencing - Technologies, Markets and Companies" to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report briefly reviews basics of human genome variations, development of sequencing technologies, and their applications. Current large and small sequencers are described as well as companies developing them. Various applications of sequencing are described including those for genetics, medical diagnostics, drug discovery and cancer. Next generation sequencing technologies, both second and third generations, are reviewed. Companies developing software for analysis of sequencing data are also included. Selected academic institutes conducting research in sequencing are also listed.

The current market is mostly for research applications and future markets will be other applications related to healthcare. The value of the DNA sequencer market in 2012 is described with estimates for 2017 and 2022. Various methods and factors on which market estimates depend are described briefly. Markets are tabulated according to geographical areas as well as applications. Small sequencers form the basis of SWOT (strengths, weaknesses, opportunities, threats) analysis. Several marketing strategies have been outlined.

The report includes profiles of 108 companies involved in sequencing and their 106 collaborations. The report text is supplemented by 36 tables, 12 figures and 320 selected references to the literature.

Key Topics Covered:

Executive Summary'/>"/>

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
4. Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
5. Animal Biotechnology - Technologies, Markets and Companies
6. Gene Therapy - Technologies, Markets and Companies
7. Biomarkers - Technologies, Markets and Companies
8. Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Cytogenetics - Technologies, Markets and Companies
10. Cell Therapy - Technologies, Markets and Companies
11. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Boston, Massachusetts (PRWEB) March 02, 2015 ... legal services, today announced the addition of Debbie Casey ... group’s capabilities in the healthcare space. , ... industry, most of which with Fresenius Medical Care North ... will leverage her extensive experience to work with Outside ...
(Date:2/28/2015)... Increasing its efforts to resolve the ... three episodes of The GMO TRUTH podcast on both ITunes ... it continues its mission to discover the truth and change ... to “uncover the truth about the GMOs in our food ... Truth Podcast is an expansion of the documentary/investigative film-making methodology ...
(Date:2/27/2015)... and SUMMERLAND, British Columbia , Feb. ... XON ), a leader in synthetic biology, today ... Okanagan Specialty Fruits (OSF), the pioneering agricultural company ... world,s first non-browning apple. Through the acquisition, Intrexon expands ... is more appetizing and convenient for consumers while providing ...
(Date:2/27/2015)... Mass. , Feb. 27, 2015 ... of the NCATS rare-diseases portfolio " in ... a new financing technique to reduce the risk ... diseases and potentially unlock new levels of funding ... The product of a unique collaboration between scientists ...
Breaking Biology Technology:Outside GC Expands Healthcare Team 2The Walk a Mile Project Launches “GMO Truth” Podcast 2Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4
... Switzerland and PARIS, October 13 Debiopharm,Group ... companies,with a focus on the development of ... Ipsen (Euronext: FR0010259150; IPN), an innovation-driven,global specialty ... of Decapeptyl(R)[1] (triptorelin embonate[2],22.5 mg) successfully completed ...
... 12 Epeius Biotechnologies Corporation today announced more stunning ... world,s first and, so far only, tumor-targeted genetic medicine ... therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has ... much-touted biologics have failed to do: that is, to ...
... study presented at the 49th Interscience Conference on Antimicrobial ... UV device to decontaminate hospital rooms at the Cleveland ... its ability to remove troublesome bacteria, including C. difficile ... germicidal energy to decontaminate air and surfaces, including those ...
Cached Biology Technology:Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 2Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 3Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 4Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 5Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 6Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 2Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 3Researchers Present 'a Novel, Automated, Efficient Environmental Disinfection Technology that Significantly Reduces C. difficile, VRE and MRSA Contamination' 2Researchers Present 'a Novel, Automated, Efficient Environmental Disinfection Technology that Significantly Reduces C. difficile, VRE and MRSA Contamination' 3
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... 2009 -- With each passing year, the human population of ... wide ranging strain on our water and soil resources, as ... the issue of food security. One way that scientists are ... seeds, both as a method of improving crop yields as ...
... Gene therapy , Gene therapy is the introduction of genetic ... a therapeutic effect. In recent years, it has been ... or even cure several fatal diseases for which there is ... for hereditary diseases, but also for other diseases that affect ...
... in safe and effective administration of potential antiviral drugs ... first step in development of a new kind of treatment ... 4 as an advance online publication of Nature Materials ... and treatment of human disease," said lead author Kim ...
Cached Biology News:Food security: It starts with seed 2Moving gene therapy forward with mobile DNA 2Nanotechnology holds promise for STD drug delivery 2
... GeneBLAzer cell-based assays utilize the membrane-permeant ... the negatively charged fluorescent beta-lactamase substrates, ... readily enter the cell, where cleavage ... them into their negatively charged forms, ...
Inquire...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Rb anti-Occludin (C-term GST)...
Biology Products: